Results 321 to 330 of about 143,566 (359)
Some of the next articles are maybe not open access.
Immune Checkpoint Blockade in Malignant Mesothelioma
Seminars in Oncology, 2015Malignant mesothelioma (MM) is a highly aggressive malignancy with a very dismal prognosis. Current treatment for unresectable MM is largely unsatisfactory; therefore, new therapeutic approaches are eagerly awaited. A better understanding of the complex mechanisms of immune escape operated by neoplastic cells and the ability to unleash an efficient ...
Calabro' L, Maio M.
openaire +3 more sources
Immunomodulation: checkpoint blockade etc.
Neuro-oncology, 2016The immune microenvironment is considered a major obstacle to generating an effective antitumor immune response. Checkpoint inhibitors manipulate the co-stimulatory response between antigen-presenting cells and immune cells-or between the tumor and immune cells-to elicit an antitumor immune response that would have otherwise been suppressed. Checkpoint
William T, Curry, Michael, Lim
openaire +2 more sources
Pseudoprogression and hyperprogression after checkpoint blockade
International Immunopharmacology, 2018Immune checkpoint inhibitors appear to be one of the most promising immunotherapies with significant clinical benefits and durable responses in multiple tumor types. A heterogeneity of responses appears in patients receiving checkpoint blockade, including pseudoprogression where the tumor burden or number of tumor lesions increases initially before ...
Qiaohong Wang, Jingze Gao, Xia Wu
openaire +2 more sources
Presurgical immune checkpoint blockade
Science, 2020Cancer Immunotherapy Checkpoint blockade immunotherapy using antibodies that inhibit the programmed cell death 1 (PD-1) or cytotoxic T lymphocyte–associated protein 4 (CTLA-4) pathways has resulted in unprecedented clinical outcomes for certain cancers such as melanoma. Topalian et al.
openaire +1 more source
Immunologic Checkpoint Blockade in Lung Cancer
Seminars in Oncology, 2015Despite the availability of radiotherapy, cytotoxic agents, and targeted agents, a high unmet medical need remains for novel therapies that improve treatment outcomes in patients with lung cancer who are ineligible for surgical resection. Building upon the early promise shown with general immunostimulatory agents, immuno-oncology is at the forefront of
Martin, Reck, Luis, Paz-Ares
openaire +2 more sources
Adding to the checkpoint blockade armamentarium
Nature Medicine, 2019Antitumor immunity can be enhanced by blocking NKG2A, an inhibitory receptor expressed on natural killer and T cells.
Matthew D. Hellmann, Alexandra Snyder
openaire +2 more sources
Delivery Strategies for Immune Checkpoint Blockade
Advanced Healthcare Materials, 2018AbstractImmune checkpoint blockade, which blocks the regulatory pathways that express on immune cells to improve antitumor immunological responses, is becoming one of the most promising approaches for antitumor therapy. This therapy has achieved important clinical advancement and provided a new opportunity against a variety of cancers.
Qian Chen +4 more
openaire +2 more sources
Combining chemotherapy and immune checkpoint blockade
Current Opinion in Urology, 2016Immune checkpoint blockade results in durable responses in a subset of patients with advanced urologic tumors. However, the majority of patients do not respond to single agent therapy raising the hypothesis that combination regimens may extend the benefits of immune checkpoint blockade to an even broader patient population.
Ana, Collazo-Lorduy, Matthew D, Galsky
openaire +2 more sources
Adjuvant immune checkpoint blockade revisited
The Lancet Oncology, 2023Sahar Barjesteh, van Waalwijk van Doorn-Khosrovani +6 more
openaire +2 more sources